Brienne A McKenzie1, Franz J Zemp1, Alexandra Pisklakova1, Aru Narendran1, Grant McFadden1, Xueqing Lun1, Rajappa S Kenchappa1, Ebba U Kurz1, Peter A Forsyth1. 1. Southern Alberta Cancer Research Institute, University of Calgary, Calgary, Canada (B.A.M., F.J.Z., A.N., X.L, E.U.K, P.A.F.); Department of Pediatrics, University of Calgary, Calgary, Canada (A.N.); Department of Oncology, University of Calgary, Calgary, Canada (A.N., P.A.F.); Department of Physiology & Pharmacology, University of Calgary, Calgary, Canada (E.U.K.); Department of Neuro-Oncology, Moffitt Cancer Center, Tampa, Florida (A.P., R.S.K, P.A.F.); Department of Molecular Genetics & Microbiology, University of Florida, Gainesville, Florida (G.M.).
Abstract
BACKGROUND: Brain tumor-initiating cells (BTICs) are stem-like cells hypothesized to form a disease reservoir that mediates tumor recurrence in high-grade gliomas. Oncolytic virotherapy uses replication-competent viruses to target and kill malignant cells and has been evaluated in clinic for glioma therapy with limited results. Myxoma virus (MyxV) is a safe and highly effective oncolytic virus (OV) in conventional glioma models but, as seen with other OVs, is only modestly effective for patient-derived BTICs. The objective of this study was to determine whether MyxV treatment against human BTICs could be improved by combining chemotherapeutics and virotherapy. METHODS: A 73-compound library of drug candidates in clinical use or preclinical development was screened to identify compounds that sensitize human BTICs to MyxV treatment in vitro, and synergy was evaluated mathematically in lead compounds using Chou-Talalay analyses. The effects of combination therapy on viral gene expression and viral replication were also assessed. RESULTS: Eleven compounds that enhance MyxV efficacy were identified, and 6 were shown to synergize with the virus using Chou-Talalay analyses. Four of the synergistic compounds were shown to significantly increase viral gene expression, indicating a potential mechanism for synergy. Three highly synergistic compounds (axitinib, a VEGFR inhibitor; rofecoxib, a cyclooxygenase-2 inhibitor; and pemetrexed, a folate anti-metabolite) belong to classes of compounds that have not been previously shown to synergize with oncolytic viruses in vitro. CONCLUSIONS: This study has identified multiple novel drug candidates that synergistically improve MyxV efficacy in a preclinical BTIC glioma model.
BACKGROUND: Brain tumor-initiating cells (BTICs) are stem-like cells hypothesized to form a disease reservoir that mediates tumor recurrence in high-grade gliomas. Oncolytic virotherapy uses replication-competent viruses to target and kill malignant cells and has been evaluated in clinic for glioma therapy with limited results. Myxoma virus (MyxV) is a safe and highly effective oncolytic virus (OV) in conventional glioma models but, as seen with other OVs, is only modestly effective for patient-derived BTICs. The objective of this study was to determine whether MyxV treatment against humanBTICs could be improved by combining chemotherapeutics and virotherapy. METHODS: A 73-compound library of drug candidates in clinical use or preclinical development was screened to identify compounds that sensitize humanBTICs to MyxV treatment in vitro, and synergy was evaluated mathematically in lead compounds using Chou-Talalay analyses. The effects of combination therapy on viral gene expression and viral replication were also assessed. RESULTS: Eleven compounds that enhance MyxV efficacy were identified, and 6 were shown to synergize with the virus using Chou-Talalay analyses. Four of the synergistic compounds were shown to significantly increase viral gene expression, indicating a potential mechanism for synergy. Three highly synergistic compounds (axitinib, a VEGFR inhibitor; rofecoxib, a cyclooxygenase-2 inhibitor; and pemetrexed, a folate anti-metabolite) belong to classes of compounds that have not been previously shown to synergize with oncolytic viruses in vitro. CONCLUSIONS: This study has identified multiple novel drug candidates that synergistically improve MyxV efficacy in a preclinical BTIC glioma model.
Authors: Kathryn Ottolino-Perry; Jean-Simon Diallo; Brian D Lichty; John C Bell; J Andrea McCart Journal: Mol Ther Date: 2009-12-22 Impact factor: 11.454
Authors: Arnold I Freeman; Zichria Zakay-Rones; John M Gomori; Eduard Linetsky; Linda Rasooly; Evgeniya Greenbaum; Shira Rozenman-Yair; Amos Panet; Eugene Libson; Charles S Irving; Eithan Galun; Tali Siegal Journal: Mol Ther Date: 2005-10-28 Impact factor: 11.454
Authors: V Papanastassiou; R Rampling; M Fraser; R Petty; D Hadley; J Nicoll; J Harland; R Mabbs; M Brown Journal: Gene Ther Date: 2002-03 Impact factor: 5.250
Authors: Franz J Zemp; Xueqing Lun; Brienne A McKenzie; Hongyuan Zhou; Lori Maxwell; Beichen Sun; John J P Kelly; Owen Stechishin; Artee Luchman; Samuel Weiss; J Gregory Cairncross; Mark G Hamilton; Brian A Rabinovich; Masmudur M Rahman; Mohamed R Mohamed; Sherin Smallwood; Donna L Senger; John Bell; Grant McFadden; Peter A Forsyth Journal: Neuro Oncol Date: 2013-04-12 Impact factor: 12.300
Authors: S Harrow; V Papanastassiou; J Harland; R Mabbs; R Petty; M Fraser; D Hadley; J Patterson; S M Brown; R Rampling Journal: Gene Ther Date: 2004-11 Impact factor: 5.250
Authors: Roberto Pallini; Lucia Ricci-Vitiani; Giuseppe Luigi Banna; Michele Signore; Dario Lombardi; Matilde Todaro; Giorgio Stassi; Maurizio Martini; Giulio Maira; Luigi Maria Larocca; Ruggero De Maria Journal: Clin Cancer Res Date: 2008-12-15 Impact factor: 12.531
Authors: Peter Forsyth; Gloria Roldán; David George; Carla Wallace; Cheryl Ann Palmer; Don Morris; Gregory Cairncross; Maureen Vallee Matthews; James Markert; Yancey Gillespie; Matt Coffey; Brad Thompson; Mark Hamilton Journal: Mol Ther Date: 2008-02-05 Impact factor: 11.454
Authors: H C A Graat; M A Witlox; F H E Schagen; G J L Kaspers; M N Helder; J Bras; G R Schaap; W R Gerritsen; P I J M Wuisman; V W van Beusechem Journal: Br J Cancer Date: 2006-05-30 Impact factor: 7.640
Authors: Jian Chen; Yanjiao Li; Tzong-Shiue Yu; Renée M McKay; Dennis K Burns; Steven G Kernie; Luis F Parada Journal: Nature Date: 2012-08-23 Impact factor: 49.962
Authors: Dipongkor Saha; Hiroaki Wakimoto; Cole W Peters; Slawomir J Antoszczyk; Samuel D Rabkin; Robert L Martuza Journal: Clin Cancer Res Date: 2018-03-29 Impact factor: 12.531
Authors: Alexandra Pisklakova; Brienne McKenzie; Franz Zemp; Xueqing Lun; Rajappa S Kenchappa; Arnold B Etame; Masmudur M Rahman; Karlyne Reilly; Shari Pilon-Thomas; Grant McFadden; Ebba Kurz; Peter A Forsyth Journal: Neuro Oncol Date: 2016-03-08 Impact factor: 12.300
Authors: L M E Berghauser Pont; R K Balvers; J J Kloezeman; M O Nowicki; W van den Bossche; A Kremer; H Wakimoto; B G van den Hoogen; S Leenstra; C M F Dirven; E A Chiocca; S E Lawler; M L M Lamfers Journal: Gene Ther Date: 2015-07-21 Impact factor: 5.250
Authors: Anna M Czarnecka; Cezary Szczylik; Zofia F Bielecka; Agata Malinowska; Klaudia K Brodaczewska; Aleksandra Klemba; Claudine Kieda; Paweł Krasowski; Elżbieta Grzesiuk; Jan Piwowarski Journal: Cell Biosci Date: 2017-12-16 Impact factor: 7.133
Authors: Irina A Tarasova; Alesya V Tereshkova; Anna A Lobas; Elizaveta M Solovyeva; Alena S Sidorenko; Vladimir Gorshkov; Frank Kjeldsen; Julia A Bubis; Mark V Ivanov; Irina Y Ilina; Sergei A Moshkovskii; Peter M Chumakov; Mikhail V Gorshkov Journal: Oncotarget Date: 2017-11-29